Genetic Signatures Reports $14.8M Revenue and $14M Loss in FY2026

Loss Reduction Reflects Strategic Reset and Cost Discipline

Genetic Signatures Limited (ASX:GSS) reported a 30% reduction in its net loss for the year ended 30 June 2026, trimming the deficit to $14 million from $20.1 million in FY2025. This improvement came despite a 7% dip in revenue to $14.8 million, reflecting a competitive and price-sensitive market alongside a delayed respiratory testing season in Australia. The company’s operational cash outflows also improved by 37% to $7.8 million, supported by a leaner cost base following a major organisational restructure.

Organisational Restructure and Cost Savings Drive Sustainability

In March 2026, Genetic Signatures completed a strategic review under new CEO Maria Halasz, who took the helm in the same month. The review led to a comprehensive organisational restructuring, including 30 redundancies across five divisions and a shift of certain product development activities to specialist contract research organisations. These changes are expected to deliver annualised cost savings of up to $5 million from FY2027, underpinning a more sustainable operating model. One-off redundancy costs of $0.8 million were recognised in FY2026.

New Long-Term Contract in Denmark Signals EMEA Growth

Genetic Signatures secured a significant 10-year supply agreement with Hvidovre Hospital, one of Denmark’s leading public hospitals, marking a milestone in its European expansion. Installation and validation of equipment were completed during FY2026, with the first commercial reagent order delivered in August 2026 and testing now underway. This contract complements ongoing growth in the EMEA region, where revenue was $1.4 million, supported by new account onboarding and rising demand for infection prevention and control in hospitals.

Strategic Shift on Automation and Product Portfolio

The company paused its in-house development of a customised liquid handling automation platform as part of the strategic reset. Instead, it is evaluating partnerships with established third-party manufacturers to provide off-the-shelf robotics solutions, aiming to reduce development risk and accelerate time to market. Concurrently, Genetic Signatures is broadening its respiratory and enteric pathogen detection assay portfolios, including outsourcing development of a new enteric pathogen detection product, to leverage its proprietary 3base® technology and expand revenue streams.

Market Dynamics and Regional Performance

Australia remains the company’s core market, generating $13.2 million in revenue despite a muted respiratory testing season and ongoing pricing pressures. The EasyScreen™ assays continue to be embedded in laboratory workflows under long-term supply agreements. In the United States, Genetic Signatures booked initial sales of $0.2 million but has decided to reset its market access strategy before further resource allocation, reflecting a cautious approach to building a profitable US presence.

Financial Position and Leadership Changes

Genetic Signatures closed FY2026 with $22.1 million in cash and term deposits, maintaining a debt-free balance sheet and sufficient runway to fund its growth plans. Leadership transitions included the appointment of Maria Halasz as CEO and a temporary stewardship by Anne Lockwood as interim Managing Director, with former CEO Allison Rossiter and CFO Karl Pechmann departing early in the year. Dr Neil Gunn also resigned from the board in May 2026. The company’s refreshed purpose now centres the patient in its mission, aiming to deliver meaningful innovations in molecular diagnostics.